Syndax Pharmaceuticals Inc·4

Jul 11, 9:23 AM ET

Morrison Briggs 4

4 · Syndax Pharmaceuticals Inc · Filed Jul 11, 2023

Insider Transaction Report

Form 4
Period: 2023-07-10
Morrison Briggs
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Stock Options (Right to buy)

    2023-07-1052,8550 total
    Exercise: $8.77Exp: 2027-02-06Common Stock (52,855 underlying)
  • Sale

    Common Stock

    2023-07-10$20.40/sh52,855$1,078,06817,836 total
  • Exercise/Conversion

    Common Stock

    2023-07-10$8.77/sh+52,855$463,53870,691 total
Footnotes (3)
  • [F1]Following the sales reported in this Form 4, the Reporting Person has a total of 601,143 options to purchase shares of common stock that are vested and immediately exercisable and a total of 258,729 options to purchase shares of common stock that have not yet vested.
  • [F2]The sale prices ranged from $20.11 to $20.71.
  • [F3]This option is fully vested.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT